Gazyva Succeeds In NOBILITY Lupus Nephritis Study But What Next?
Executive Summary
Genentech refrained from committing to further development of its CD20 inhibitor in the indication despite meeting endpoints in Phase II study.
You may also be interested in...
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Roche’s Pipeline Prospects Promise Steady Sailing To More Growth
Analysts increasingly see Roche’s pipeline and newly launched drugs winning over investors and neutralizing worries over biosimilars and potential US pricing reforms. Its 16 September pipeline update in London may reinforce that.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Need a specific report? 1000+ reports available
Buy Reports